EGFR and non-small cell lung carcinoma: In a subgroup analysis of the phase III FLAURA trial, osimertinib, a third-generation EGFR TKI, compared to erlotinib or gefitinib in a population of treatment-naïve, EGFRm NSCLC patients, was associated with a 52% reduction in the risk of CNS progression or death due to its superior ability to cross the BBB [48].